347 related articles for article (PubMed ID: 28221865)
21. Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis.
Yang Y; Pei J; Gao G; Yang Z; Guo S; Yue B; Qiu J
Oncotarget; 2016 Dec; 7(49):80855-80871. PubMed ID: 27764796
[TBL] [Abstract][Full Text] [Related]
22. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
Algazi AP; Cha E; Ortiz-Urda SM; McCalmont T; Bastian BC; Hwang J; Pampaloni MH; Behr S; Chong K; Cortez B; Quiroz A; Coakley F; Liu S; Daud AI
Br J Cancer; 2015 Apr; 112(8):1326-31. PubMed ID: 25867272
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral administration of the immunologic adjuvant AS01
Tijtgat J; Geeraerts X; Boisson A; Stevens L; Vounckx M; Dirven I; Schwarze JK; Raeymaeckers S; Forsyth R; Van Riet I; Tuyaerts S; Willard-Gallo K; Neyns B
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212127
[TBL] [Abstract][Full Text] [Related]
24. Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma.
Glutsch V; Kneitz H; Gesierich A; Goebeler M; Haferkamp S; Becker JC; Ugurel S; Schilling B
Cancer Immunol Immunother; 2021 Jul; 70(7):2087-2093. PubMed ID: 33439294
[TBL] [Abstract][Full Text] [Related]
25. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
Vasudev NS; Ainsworth G; Brown S; Pickering L; Waddell T; Fife K; Griffiths R; Sharma A; Katona E; Howard H; Velikova G; Maraveyas A; Brown J; Pezaro C; Tuthill M; Boleti E; Bahl A; Szabados B; Banks RE; Brown J; Venugopal B; Patel P; Jain A; Symeonides SN; Nathan P; Collinson FJ; Powles T
J Clin Oncol; 2024 Jan; 42(3):312-323. PubMed ID: 37931206
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective.
Brodtkorb TH; Knight C; Kamgar F; Teitsson S; Kurt M; Patel MY; Poretta T; Mamtani R; Palmer S
J Med Econ; 2024; 27(1):543-553. PubMed ID: 38470512
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.
Ten Ham RMT; Rohaan MW; Jedema I; Kessels R; Stegeman W; Scheepmaker W; Nuijen B; Nijenhuis C; Lindenberg M; Borch TH; Monberg T; Donia M; Marie Svane I; van Harten W; Haanen J; Retel VP
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38531663
[TBL] [Abstract][Full Text] [Related]
28. Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report.
Takada R; Fujiwara M; Maki M; Nomura N; Kono S; Fujita A; Masumoto H; Takahashi Y; Hasegawa Y; Tamura K
J Pharm Health Care Sci; 2024 May; 10(1):26. PubMed ID: 38822426
[TBL] [Abstract][Full Text] [Related]
29. Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial.
Ascierto PA; Vanella V; Grimaldi AM; Lucia F; Palla M; Simeone E; Mozzillo N
Cancer Immunol Immunother; 2016 Nov; 65(11):1395-1400. PubMed ID: 27604993
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma.
Ascierto PA
Cancer Immunol Immunother; 2015 Mar; 64(3):271-4. PubMed ID: 25549844
[TBL] [Abstract][Full Text] [Related]
31. Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.
Gibson E; Koblbauer I; Begum N; Dranitsaris G; Liew D; McEwan P; Tahami Monfared AA; Yuan Y; Juarez-Garcia A; Tyas D; Lees M
Pharmacoeconomics; 2017 Dec; 35(12):1257-1270. PubMed ID: 28866758
[TBL] [Abstract][Full Text] [Related]
32. Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
Cao Y; Afzal MZ; Gutmann EJ; Shirai K
Melanoma Res; 2024 Feb; 34(1):70-75. PubMed ID: 37830935
[TBL] [Abstract][Full Text] [Related]
33. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.
Parra ER; Zhang J; Duose DY; Gonzalez-Kozlova E; Redman MW; Chen H; Manyam GC; Kumar G; Zhang J; Song X; Lazcano R; Marques-Piubelli ML; Laberiano-Fernandez C; Rojas F; Zhang B; Taing L; Jhaveri A; Geisberg J; Altreuter J; Michor F; Provencher J; Yu J; Cerami E; Moravec R; Kannan K; Luthra R; Alatrash G; Huang HH; Xie H; Patel M; Nie K; Harris J; Argueta K; Lindsay J; Biswas R; Van Nostrand S; Kim-Schulze S; Gray JE; Herbst RS; Wistuba II; Gettinger S; Kelly K; Bazhenova L; Gnjatic S; Lee JJ; Zhang J; Haymaker C
Clin Cancer Res; 2024 Apr; 30(8):1655-1668. PubMed ID: 38277235
[TBL] [Abstract][Full Text] [Related]
34. A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma.
Fedele D; Moroso S; Turoldo A; Bazzocchi G; Conforti C; Zalaudek I; Guglielmi A
Case Rep Oncol; 2024; 17(1):161-168. PubMed ID: 38288458
[TBL] [Abstract][Full Text] [Related]
35. The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.
Numakura K; Sekine Y; Osawa T; Naito S; Tokairin O; Muto Y; Sobu R; Kobayashi M; Sasagawa H; Yamamoto R; Nara T; Saito M; Narita S; Akashi H; Tsuchiya N; Shinohara N; Habuchi T
Int J Clin Oncol; 2024 May; ():. PubMed ID: 38797782
[TBL] [Abstract][Full Text] [Related]
36. Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors.
Nishizawa A; Kawakami M; Kitahara Y
Front Oncol; 2024; 14():1366532. PubMed ID: 38529375
[TBL] [Abstract][Full Text] [Related]
37. Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study.
Smithy JW; Kalvin HL; Ehrich FD; Shah R; Adamow M; Raber V; Maher CA; Kleman J; McIntyre DAG; Shoushtari AN; Betof Warner A; Callahan MK; Momtaz P; Eton O; Nair S; Wolchok JD; Chapman PB; Berger MF; Panageas KS; Postow MA
Clin Cancer Res; 2024 May; ():. PubMed ID: 38767650
[TBL] [Abstract][Full Text] [Related]
38. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes.
Chae YK; Chiec L; Mohindra N; Gentzler R; Patel J; Giles F
Cancer Immunol Immunother; 2017 Jan; 66(1):25-32. PubMed ID: 27761609
[TBL] [Abstract][Full Text] [Related]
39. Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma.
Hu Y; Briggs A; Marchetti MA; Ariyan CE; Coit DG; Bartlett EK
J Am Coll Surg; 2020 Nov; 231(5):547-554.e1. PubMed ID: 32889093
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab treatment in a patient with BRAF mutant advanced melanoma and liver failure with encephalopathy.
Colak R; Kapar C; Gulturk I; Yilmaz M
J Oncol Pharm Pract; 2024 Apr; 30(3):589-593. PubMed ID: 38111303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
